
    
      The primary objective of this research is to determine whether treatment with either insulin
      or an oral diabetes agent that increases endogenous insulin secretion will improve BMI and
      pulmonary function in cystic fibrosis patients who have diabetes without fasting
      hyperglycemia.
    
  